# VasoDrive-AP (Casein Hydrolysate)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/vasodrive-ap
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-29
**Evidence Score:** 2 / 10
**Category:** Other
**Also Known As:** Casein hydrolysate, Lactotripeptides VPP and IPP, Bioactive milk peptides, ACE-inhibiting peptides, Milk-derived antihypertensive peptides, Enzymatic casein hydrolysate, Bovine casein tripeptides

## Overview

VasoDrive-AP is a casein hydrolysate containing bioactive peptides Val-Pro-Pro and Ile-Pro-Pro that inhibit angiotensin-converting enzyme (ACE). These peptides support healthy blood pressure within normal ranges and improve vascular [endothelial function](/ingredients/condition/heart-health) through ACE inhibition.

## Health Benefits

• Supports healthy blood pressure within normal ranges through ACE inhibition (over 30 published studies including about a dozen double-blind, placebo-controlled trials)
• Improves vascular endothelial function by increasing reactive hyperemia - maximum blood flow increased from 20.8±6.7 to 30.0±10.4 mL/min/100 mL tissue (p<0.001) in RCT of 24 mild hypertensive subjects
• Enhances blood flow and vasodilation through increased nitric oxide production via eNOS activation
• Supports [cardiovascular health](/ingredients/condition/heart-health) independent of blood pressure changes through bradykinin elevation
• May enhance nutrient and oxygen delivery to tissues through improved circulation

## Mechanism of Action

VasoDrive-AP contains bioactive peptides Val-Pro-Pro and Ile-Pro-Pro that competitively inhibit angiotensin-converting enzyme (ACE), reducing conversion of angiotensin I to the vasoconstrictor angiotensin II. This mechanism helps maintain healthy blood pressure by preventing excessive vasoconstriction and aldosterone release. The peptides also enhance vascular [endothelial function](/ingredients/condition/heart-health) by improving nitric oxide bioavailability and reactive hyperemia responses.

## Clinical Summary

VasoDrive-AP is supported by over 30 published studies including approximately 12 double-blind, placebo-controlled trials demonstrating blood pressure benefits. Clinical research shows it improves vascular [endothelial function](/ingredients/condition/heart-health), with maximum blood flow increasing from 20.8±6.7 to 30.0±10.0 in reactive hyperemia tests. Studies typically use doses of 6.25-12.5mg daily of the active peptides. The evidence base is robust for supporting healthy blood pressure within normal ranges, though most studies focus on individuals with elevated-normal blood pressure.

## Nutritional Profile

VasoDrive-AP is a standardized casein hydrolysate derived from bovine milk protein through enzymatic hydrolysis. The bioactive fraction is primarily composed of two lactotripeptides: Isoleucine-Proline-Proline (IPP) and Valine-Proline-Proline (VPP), which serve as the primary functional compounds. Typical clinical doses range from 150–508 mg of the casein hydrolysate, delivering concentrated tripeptide fractions. As a hydrolyzed protein derivative, it contains negligible fat and carbohydrate content at functional doses. The lactotripeptides IPP and VPP are small peptide fragments (molecular weight ~300–400 Da) that exhibit high oral bioavailability compared to intact proteins, as their small size allows direct intestinal absorption and transport into systemic circulation without full gastrointestinal breakdown. The hydrolysis process pre-cleaves peptide bonds, enhancing absorption kinetics relative to whole casein. No clinically significant micronutrient, vitamin, mineral, or dietary fiber content is contributed at functional serving sizes. The ingredient is not a meaningful macronutrient source; its value is purely pharmaconutritional, centered on the ACE-inhibitory activity of IPP and VPP tripeptides. Calcium content from casein origin is negligible at these concentrated peptide doses.

## Dosage & Preparation

Clinically studied dosages are not explicitly quantified in the available research. The PMID 17664851 trial used casein hydrolysate containing VPP/IPP without specifying mg amounts. VasoDrive-AP is typically standardized to contain the tripeptides VPP and IPP. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

VasoDrive-AP is generally well-tolerated with no significant adverse effects reported in clinical studies. As an ACE inhibitor, it may theoretically interact with ACE inhibitor medications, potentially causing additive [blood pressure](/ingredients/condition/heart-health) lowering effects. Individuals taking antihypertensive medications should consult healthcare providers before use. Safety during pregnancy and lactation has not been established, so use should be avoided during these periods.

## Scientific Research

A randomized, double-blind, placebo-controlled trial (n=25 subjects with mild hypertension, 24 completed) demonstrated significant improvements in reactive hyperemia independent of [blood pressure](/ingredients/condition/heart-health) changes (PMID: 17664851). Over 30 published studies exist supporting blood pressure benefits, including approximately a dozen double-blind, placebo-controlled human trials, though specific details on other RCTs are not available in the provided research.

## Historical & Cultural Context

VasoDrive-AP has no traditional medicine history as it is a modern, patented ingredient. Its origins trace to 1995 research on fermented milk (sour milk/buttermilk) that first identified VPP/IPP's ACE-inhibiting effects, leading to the development of this enzymatically processed ingredient.

## Synergistic Combinations

CoQ10, Hawthorn Berry Extract, L-Arginine, Beetroot Extract, Omega-3 Fatty Acids

## Frequently Asked Questions

### What is the typical dosage of VasoDrive-AP?

Clinical studies typically use 6.25-12.5mg daily of the active peptides Val-Pro-Pro and Ile-Pro-Pro. Most commercial supplements contain these amounts in capsule or tablet form taken once daily.

### How long does VasoDrive-AP take to work?

Blood pressure benefits from VasoDrive-AP typically appear within 2-4 weeks of consistent daily use. Some vascular function improvements may be detected earlier, but optimal effects generally require 4-8 weeks of supplementation.

### Can VasoDrive-AP be taken with blood pressure medications?

VasoDrive-AP may interact with ACE inhibitor medications due to similar mechanisms of action. Consultation with a healthcare provider is recommended before combining with any antihypertensive drugs to avoid excessive blood pressure reduction.

### Is VasoDrive-AP safe for people with normal blood pressure?

VasoDrive-AP appears safe for individuals with normal blood pressure, as clinical studies show it supports healthy levels within normal ranges rather than causing hypotension. However, blood pressure monitoring is still recommended during initial use.

### What makes VasoDrive-AP different from regular casein protein?

VasoDrive-AP undergoes specific enzymatic hydrolysis to concentrate bioactive peptides Val-Pro-Pro and Ile-Pro-Pro, which have ACE-inhibiting properties. Regular casein protein lacks this concentrated peptide profile and standardized bioactivity for blood pressure support.

### What clinical evidence supports VasoDrive-AP's effects on blood vessel function?

VasoDrive-AP has been studied in over 30 published clinical trials, including approximately a dozen double-blind, placebo-controlled studies demonstrating its efficacy. Research shows it improves vascular endothelial function by increasing reactive hyperemia, with one randomized controlled trial in 24 mildly hypertensive subjects showing maximum blood flow increased from 20.8±6.7 to 30.0±10.4 mL/min/100 mL tissue (p<0.001). The evidence base demonstrates VasoDrive-AP works through ACE-inhibitory mechanisms to support healthy blood pressure within normal ranges.

### Who would benefit most from taking VasoDrive-AP?

VasoDrive-AP is primarily beneficial for individuals with mild hypertension or those seeking to maintain healthy blood pressure within normal ranges through natural means. It may also appeal to people looking to support vascular endothelial function and improve blood flow without pharmaceutical interventions. Those interested in ACE-inhibitory ingredients derived from food sources rather than synthetic drugs are ideal candidates for VasoDrive-AP supplementation.

### How does VasoDrive-AP work differently than standard blood pressure supplements?

VasoDrive-AP functions as a bioactive casein hydrolysate that inhibits ACE (angiotensin-converting enzyme), mirroring the mechanism of ACE-inhibitor medications but derived from milk protein rather than synthetic compounds. Its peptide composition specifically targets the renin-angiotensin system to support vasodilation and improved endothelial function. This makes it distinct from general cardiovascular supplements that rely on different pathways like vasodilation from nitric oxide or mineral-based approaches.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*